A carregar...
Mifepristone Treatment Promotes Testicular Leydig Cell Tumor Progression in Transgenic Mice
SIMPLE SUMMARY: Recently, the antiprogestin activity of selective progesterone receptor (PR) modulator mifepristone (MF) has proven unsuccessful as a potential anti-cancer agent in various clinical trials. Herein, we analyzed the effects of MF treatment on Leydig cell tumor (LCT) progression in a tr...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7694279/ https://ncbi.nlm.nih.gov/pubmed/33158280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113263 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|